Roche Calls In Genentech; Will Reduced Reissue Restore Independence?
Executive Summary
Genentech's "independence" in the future will be based on a larger presence by Roche on the board, a smaller percentage of publicly traded shares, and more risk exposure for those smaller public holdings.